Nikolai Brun appointed new Director of Division
The Danish Medicines Agency strengthens its leadership team and appoints Nikolai Brun, MD and PhD, as Director of Division of the new Medical Evaluation & Biostatistics division.
Nikolai Brun comes from a position as senior vice president in the drug development company Serodus and has many years of experience in drug development from executive positions in Novo Nordisk A/S, Genzyme and Genmab.
”With the appointment of Nikolai Brun, we have a very competent head of the new Medical Evaluation & Biostatistics division. Nikolai is highly respected in haematology and oncology medicine and he is the right person to help us realise our vision of strengthening the scientific advice to companies and gaining an even stronger presence in Europe,” says Thomas Senderovitz, Director General of the Danish Medicines Agency.
Nikolai Brun will take up the new position at the Danish Medicines Agency on 1 March 2017.
”After many years as a drug developer in the industry, it is time to try something different. The Danish Medicines Agency is in an exciting development phase, and I look forward to joining the leadership team that aims to create a Danish Medicines Agency in European top class as described in the recently launched strategy,” says Nikolai Brun.
Nikolai Brun is appointed Director of Division of the new Medical Evaluation & Biostatistics division.